Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series

Rhea-AI Summary

Whitehawk Therapeutics (NASDAQ: WHWK), a company focused on developing advanced ADC cancer treatments, announced its participation in the H.C. Wainwright virtual "HCW@Home" series. The company's President and CEO Dave Lennon, PhD, and Chief Scientific Officer David Dornan, PhD, will present on Thursday, June 26, 2025, at 10 AM ET. The presentation will be accessible via webcast on the company's website under the "Investors & News" section, with replay available for approximately 30 days after the event.

News Market Reaction – WHWK

+1.95%

+1.95% Session move

In the trading session that priced this news, WHWK gained 1.95%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025, at 10 AM ET.

To register in advance, please use this link. A live webcast of the event can be accessed by visiting the "Investors & News" page on the Whitehawk Therapeutics website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics 

Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact
IR@whitehawktx.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-hc-wainwright-hcwhome-series-302485848.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

When is Whitehawk Therapeutics (WHWK) presenting at the H.C. Wainwright conference?

Whitehawk Therapeutics will present at the H.C. Wainwright HCW@Home series on Thursday, June 26, 2025, at 10 AM ET.

Who will be presenting for Whitehawk Therapeutics (WHWK) at the H.C. Wainwright conference?

Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will be presenting for Whitehawk Therapeutics.

How can I access Whitehawk Therapeutics (WHWK) H.C. Wainwright presentation?

The presentation can be accessed via webcast on the Investors & News page of Whitehawk Therapeutics' website, with replay available for approximately 30 days.

What is Whitehawk Therapeutics' (WHWK) main business focus?

Whitehawk Therapeutics is an oncology therapeutics company that applies advanced technologies to established tumor biology to deliver improved ADC cancer treatments.